126 related articles for article (PubMed ID: 38897411)
1. Pharmacogenetic implementation for CYP2C19 and pharmacokinetics of voriconazole in children with malignancy or inborn errors of immunity.
Shoji K; Hikino K; Saito J; Matsui T; Utano T; Takebayashi A; Tomizawa D; Kato M; Matsumoto K; Ishikawa T; Kawai T; Nakamura H; Miyairi I; Terao C; Mushiroda T
J Infect Chemother; 2024 Jun; ():. PubMed ID: 38897411
[TBL] [Abstract][Full Text] [Related]
2. Combined Effect of
Chen J; Wu Y; He Y; Feng X; Ren Y; Liu S
Front Pediatr; 2022; 10():846411. PubMed ID: 35386257
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic drug monitoring and
Chen X; Xiao Y; Li H; Huang Z; Gao J; Zhang X; Li Y; Van Timothee BM; Feng X
Transl Pediatr; 2022 Aug; 11(8):1311-1322. PubMed ID: 36072540
[TBL] [Abstract][Full Text] [Related]
4. Putting CYP2C19 genotyping to the test: utility of pharmacogenomic evaluation in a voriconazole-treated haematology cohort.
Trubiano JA; Crowe A; Worth LJ; Thursky KA; Slavin MA
J Antimicrob Chemother; 2015 Apr; 70(4):1161-5. PubMed ID: 25558073
[TBL] [Abstract][Full Text] [Related]
5. The impact of
de Jong LM; Boussallami S; Sánchez-López E; Giera M; Tushuizen ME; Hoekstra M; Hawinkels LJAC; Rissmann R; Swen JJ; Manson ML
Front Pharmacol; 2023; 14():1201906. PubMed ID: 37361233
[No Abstract] [Full Text] [Related]
6. Model-Oriented Dose Optimization of Voriconazole in Critically Ill Children.
Wang J; Xu H; Li R; Wu S; Zou J; Wang Y
Antimicrob Agents Chemother; 2021 Aug; 65(9):e0049321. PubMed ID: 34152812
[TBL] [Abstract][Full Text] [Related]
7. Correlation of CYP2C19 phenotype with voriconazole plasma concentration in children.
Narita A; Muramatsu H; Sakaguchi H; Doisaki S; Tanaka M; Hama A; Shimada A; Takahashi Y; Yoshida N; Matsumoto K; Kato K; Kudo K; Furukawa-Hibi Y; Yamada K; Kojima S
J Pediatr Hematol Oncol; 2013 Jul; 35(5):e219-23. PubMed ID: 23588332
[TBL] [Abstract][Full Text] [Related]
8. CYP2C19 Phenotype and Body Weight-Guided Voriconazole Initial Dose in Infants and Children after Hematopoietic Cell Transplantation.
Takahashi T; Mohamud MA; Smith AR; Jacobson PA; Jaber MM; Alharbi AF; Fisher J; Kirstein MN
Antimicrob Agents Chemother; 2021 Aug; 65(9):e0062321. PubMed ID: 34097481
[TBL] [Abstract][Full Text] [Related]
9. Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing.
Dolton MJ; Mikus G; Weiss J; Ray JE; McLachlan AJ
J Antimicrob Chemother; 2014 Jun; 69(6):1633-41. PubMed ID: 24554646
[TBL] [Abstract][Full Text] [Related]
10. A Prospective Study on the Usefulness of Initial Voriconazole Dose Adjustment Based on CYP2C19 Gene Polymorphism Analysis.
Tanaka R; Fujioka T; Suzuki Y; Iwao M; Itoh H
Chemotherapy; 2020; 65(3-4):59-64. PubMed ID: 32877905
[TBL] [Abstract][Full Text] [Related]
11. Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections.
Hamadeh IS; Klinker KP; Borgert SJ; Richards AI; Li W; Mangal N; Hiemenz JW; Schmidt S; Langaee TY; Peloquin CA; Johnson JA; Cavallari LH
Pharmacogenet Genomics; 2017 May; 27(5):190-196. PubMed ID: 28306618
[TBL] [Abstract][Full Text] [Related]
12. Dosage optimization of voriconazole in children with haematological malignancies based on population pharmacokinetics.
Wu Y; Lv C; Wu D; Qi J; Cai R; Zhou S; Li C; Wei Y; Liu T
J Clin Pharm Ther; 2022 Dec; 47(12):2245-2254. PubMed ID: 36345158
[TBL] [Abstract][Full Text] [Related]
13. [The relationship between genetic polymorphism of CYP2C19 and the efficacy of
Luo LL; Chen B; Shu XL; Zheng W; Long G; Jiang MZ
Zhonghua Er Ke Za Zhi; 2023 Jul; 61(7):600-605. PubMed ID: 37385802
[No Abstract] [Full Text] [Related]
14. Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study.
Blanco-Dorado S; Maroñas O; Latorre-Pellicer A; Rodríguez Jato MT; López-Vizcaíno A; Gómez Márquez A; Bardán García B; Belles Medall D; Barbeito Castiñeiras G; Pérez Del Molino Bernal ML; Campos-Toimil M; Otero Espinar F; Blanco Hortas A; Durán Piñeiro G; Zarra Ferro I; Carracedo Á; Lamas MJ; Fernández-Ferreiro A
Pharmacotherapy; 2020 Jan; 40(1):17-25. PubMed ID: 31782536
[TBL] [Abstract][Full Text] [Related]
15. Effect of cytochrome P450 2C19 polymorphisms on the clinical outcomes of voriconazole: a systematic review and meta-analysis.
Li X; Yu C; Wang T; Chen K; Zhai S; Tang H
Eur J Clin Pharmacol; 2016 Oct; 72(10):1185-1193. PubMed ID: 27388292
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetic Expression of CYP2C19 in a Pediatric Population.
Pierre-François MJD; Gagné V; Brukner I; Krajinovic M
J Pers Med; 2022 Aug; 12(9):. PubMed ID: 36143168
[TBL] [Abstract][Full Text] [Related]
17. Effects of CYP2C19, CYP2C9 and CYP3A4 gene polymorphisms on plasma voriconazole levels in Chinese pediatric patients.
Fan X; Zhang H; Wen Z; Zheng X; Yang Y; Yang J
Pharmacogenet Genomics; 2022 Jun; 32(4):152-158. PubMed ID: 35081606
[TBL] [Abstract][Full Text] [Related]
18. Impact of flavin-containing monooxygenase 3 and CYP2C19 genotypes on plasma disposition and adverse effects of voriconazole administered orally in immunocompromised patients.
Yamada T; Mino Y; Naito T; Kawakami J
J Infect Chemother; 2019 Dec; 25(12):1019-1025. PubMed ID: 31239195
[TBL] [Abstract][Full Text] [Related]
19. Interaction of age and CYP2C19 genotypes on voriconazole steady-state trough concentration in Chinese patients.
Du YX; Zhu YX; Li L; Yang J; Chen XP
Pharmacogenet Genomics; 2024 May; ():. PubMed ID: 38747453
[TBL] [Abstract][Full Text] [Related]
20. Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers.
Lee S; Kim BH; Nam WS; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
J Clin Pharmacol; 2012 Feb; 52(2):195-203. PubMed ID: 21383338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
